Why Catalyst Pharmaceuticals (CPRX) is Back on Investors’ Radar

Catalyst Pharmaceuticals (CPRX) has drawn attention after a mixed stretch in the stock, with a small month gain but a decline over the past 3 months and past year. This has prompted fresh interest in its fundamentals.

At a share price of US$23.40, Catalyst’s recent 1 day share price return of a 3.51% decline and 7 day gain of 2.68% contrast with a softer 1 year total shareholder return of a 5.22% decline. Over 5 years, the total shareholder return is described as very large, suggesting long term holders have seen strong compounding while short term momentum has faded.

If this kind of mixed performance has you thinking about where else growth could come from in healthcare and biotech, it can help to broaden your view with 34 healthcare AI stocks.

With Catalyst reporting US$589 million in revenue, US$214 million in net income, a very large 5 year total return and what appears to be a sizeable intrinsic and analyst price discount, is this a genuine opportunity or is future growth already priced in?

Price-to-Earnings of 13.3x: Is it justified?

On a P/E of 13.3x at a last close of $23.40, Catalyst Pharmaceuticals screens as good value compared with both its own fair P/E estimate and key biotech peers.

The P/E ratio compares the share price with earnings per share, so it reflects how much investors are paying for each dollar of current profit. For a profitable rare disease business generating US$214.3 million in net income with high quality earnings and a 36.4% net margin, this is a central yardstick many investors watch.

Here, the picture is that the market is paying less per dollar of earnings than several benchmarks. The stock trades below the estimated fair P/E of 16.1x, and also below the US Biotechs industry average of 15.1x and a peer group average of 28.3x. That gap suggests the P/E level could move closer to the higher fair ratio level if earnings trends and profitability remain aligned with current expectations.

Result: Price-to-Earnings of 13.3x (UNDERVALUED)

However, there are still risks, including reliance on a small rare disease portfolio and the possibility that the current valuation already reflects much of the perceived upside.

Another View, Using the SWS DCF Model

While the P/E of 13.3x makes Catalyst Pharmaceuticals look inexpensive, the SWS DCF model goes even further and suggests a fair value of $63.97 per share versus the current $23.40. That gap points to a very different pricing story, so which signal would you lean on?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Catalyst Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 62 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of signals leaves you curious, now is a good moment to look through the numbers yourself and challenge the market’s view. To see what investors currently see as the main positives, take a closer look at the 5 key rewards

Looking for more investment ideas?

If Catalyst has sharpened your focus on quality, do not stop here. The next smart move is widening your watchlist with carefully filtered opportunities.

• Target potential mispricings by scanning a focused set of 62 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect their strengths.
• Prioritise resilience by checking a curated group of companies in the 64 resilient stocks with low risk scores that score well on financial strength and earnings stability.
• Hunt for future leaders by reviewing a handpicked screener containing 25 high quality undiscovered gems that have solid metrics but limited current attention from the market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.